Mičová Kateřina M.Sc.

Mičová Kateřina M.Sc.'s picture
Phone: +420 585632177
Doctoral training
Significance of intracellular and plasma levels of new tyrosine kinase inhibitors
The thesis is focused on development of HPLC-MS/MS methods for determination of tyrosine kinase inhibitors imatinib, nilotinib and dasatinib used for the treatment of chronic myeloid leukemia, and also on relationship between imatinib plasma levels and treatment response.



Publications (Impact Factor Journals):

  • [8]
    KARLÍKOVÁ, R., K. MIČOVÁ, L. NAJDEKR, A. GARDLO, T. ADAM, P. MAJEROVÁ, D. FRIEDECKÝ a A. KOVAC. Metabolic status of CSF distinguishes rats with tauopathy from controls. Alzheimer's Research & Therapy. 2017, 9(1), 78. ISSN 1758-9193. IF: 6.154. PMID: 28934963
  • [7]
    VROBEL, I., D. FRIEDECKÝ, E. FABER, L. NAJDEKR, K. MIČOVÁ, R. KARLÍKOVÁ a T. ADAM. Novel sulphur-containing imatinib metabolites found by untargeted LC-HRMS analysis. European Journal of Pharmaceutical Sciences. 2017, -, -. ISSN 0928-0987. IF: 3.773. PMID: 28433749
  • [6]
    KARLÍKOVÁ, R., J. ŠIROKÁ, D. FRIEDECKÝ, E. FABER, M. HRDA, K. MIČOVÁ, I. FIKAROVA, A. GARDLO, H. JANEČKOVÁ, I. VROBEL a T. ADAM. Metabolite Profiling of the Plasma and Leukocytes of Chronic Myeloid Leukemia Patients. Journal of Proteome Research. 2016, 15(9), 3158-66. ISSN 1535-3893 . IF: 4.268. PMID: 27465658
  • [5]
    VROBEL, I., H. JANEČKOVÁ, E. FABER, K. BOUCHALOVÁ, K. MIČOVÁ, D. FRIEDECKÝ a T. ADAM. Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma. Therapeutic Drug Monitoring. 2016, 38(4), 516-524. ISSN 0163-4356 . IF: 2.178. PMID: 27414975
  • [4]
    LIGASOVÁ, A., R. LIBOSKA, D. FRIEDECKÝ, K. MIČOVÁ, T. ADAM, T. OŽDIAN, I. ROSENBERG a K. KOBERNA. Dr Jekyll and Mr Hyde: A Strange Case of 5-Ethynyl-2'-deoxyuridine and 5-ethynyl-2'-deoxycytidine. Open Biology. 2016, 6: 150172, 1-11. ISSN 2046-2441. IF: 3.481. PMID: 26740587
  • [3]
    FRIEDECKÝ, D., K. MIČOVÁ, E. FABER, M. HRDA, J. ŠIROKÁ a T. ADAM. Detailed study of imatinib metabolization using high-resolution mass spectrometry. Journal of Chromatography. 2015, 1409(-), 173-181. ISSN 0021-9673. IF: 3.926. PMID: 26199102
  • [2]
    MIČOVÁ, K., D. FRIEDECKÝ, E. FABER a T. ADAM. Isotope dilution direct injection mass spectrometry method for determination of four tyrosine kinase inhibitors in human plasma. Talanta. 2012, 93(-), 307-317. ISSN 0039-9140. IF: 3.498. PMID: 22483915
  • [1]
    FABER, E., D. FRIEDECKÝ, K. MIČOVÁ, S. ROZMANOVA, M. DIVOKÁ, M. JAROSOVA, K. INDRAK a T. ADAM. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Annals of Hematology. 2012, 91(6), 923-929. ISSN 0939-5555. IF: 2.866. PMID: 22231281

Publications (Other Reviewed Journals):

  • [1]
    MIČOVÁ, K., D. FRIEDECKÝ, E. FABER a T. ADAM. Rutinní terapeutické monitorování tyrosinkinázových inhibitorů metodou LC-MS/MS. Klinická biochemie a metabolismus. 2012, 20(41), 222-225. ISSN 1210-7921.